Core Viewpoint - Zhongjing Wanshi Pharmaceutical's testing center has received the CNAS laboratory accreditation, marking its entry into the international laboratory mutual recognition framework, which enhances the quality and credibility of traditional Chinese medicine [1][3]. Group 1: CNAS Accreditation - CNAS accreditation is one of the highest authorities in laboratory testing capabilities in China, aligning with international standards such as ISO/IEC 17025, providing international credibility to the company's testing data [3]. - The accreditation allows the company to achieve mutual recognition in over 100 countries and regions, enhancing its core competitiveness and global expansion opportunities [3]. Group 2: Testing Capabilities and Innovations - The testing center is equipped with advanced detection equipment, including ICP-MS, LC-MS, and GC-MS, focusing on precision, efficiency, and rigor to ensure drug quality and safety [3]. - The center has published six papers in national core journals and holds over ten patents, demonstrating its commitment to innovation and high-standard testing services [3]. Group 3: Quality Management and Standards - Zhongjing Wanshi Pharmaceutical emphasizes quality system construction and has participated in drafting quality standards for various traditional Chinese medicine products, establishing 19 industry standards and norms [5]. - The company has implemented a comprehensive quality control mechanism from seedling to consumer, continuously improving drug standardization management [5]. - The quality technology leader stated that CNAS recognition is both an affirmation of the existing system and a motivation for future improvements, aiming to provide higher quality and more reliable traditional Chinese medicine products [5].

Core Viewpoint - The 37th Academic Exchange Conference on Spleen and Stomach Diseases organized by the Chinese Association of Traditional Chinese Medicine was successfully held, showcasing the latest clinical research and developments in the treatment of gastrointestinal diseases, particularly highlighting the unique product "Fengliao Stomach and Intestine Kang Granules" from Hainan Haiyao Co., Ltd [1][2]. Group 1: Company Developments - Hainan Haiyao presented its unique traditional Chinese medicine product, Fengliao Stomach and Intestine Kang Granules, at the conference, which has shown promising results in clinical evaluations [1][2]. - The clinical study of Fengliao Stomach and Intestine Kang Granules demonstrated its effectiveness in treating adult acute diarrhea, showing a trend of better efficacy compared to the control group [2]. - The product has received multiple registrations and certifications, including five registration approvals and two invention patents, and has been recognized in twelve treatment guidelines [2]. Group 2: Market Trends - The sales of digestive system medications in China's urban retail pharmacies have shown steady growth, with a rebound in the first quarter of 2025 reaching nearly 15 billion yuan, a year-on-year increase of 2.29% [3]. - The market for traditional Chinese medicine in digestive diseases has remained stable, with significant growth in specific categories, such as stomach medications, which accounted for 24.09% of the market share [3]. - The increasing willingness of consumers to use natural and low-side-effect traditional Chinese medicine products is expected to enhance the market prospects for Hainan Haiyao's flagship products [3]. Group 3: Research and Development - Hainan Haiyao has established a robust R&D system, focusing on innovative drugs, formulations, and traditional Chinese medicine, with significant investments in major disease areas [5][6]. - The company has invested 397 million yuan in R&D over the past three years, with 124 million yuan allocated in 2024, representing 12.48% of its revenue [5]. - Two key innovative drugs, Fluorofenone and Painegabin, are currently in Phase II clinical trials, indicating the company's commitment to advancing its drug development pipeline [6].

Group 1 - The core focus of Xixia County is on developing a "billion-level industrial chain" centered around "traditional Chinese medicine and green food" [1][2] - The county has established a "Postdoctoral Small Courtyard" research platform to attract high-end talent and enhance policy appeal through financial support and subsidies [2][5] - A comprehensive demand list has been created, including 27 project needs, 91 talent needs, and 127 technology needs, to facilitate collaboration with over 20 research institutions [2][5] Group 2 - The county has implemented a "point order" service model to address specific research needs of enterprises, leading to breakthroughs in 11 technology R&D projects and the successful production of new agricultural varieties [5][6] - A training program called "Small Courtyard Doctor Lecture Hall" has been organized to enhance agricultural talent, resulting in the education of over 220 agricultural technicians and the creation of more than 30 leading agricultural enterprises [6]

Economic Performance - In the first quarter, Chongzuo's GDP reached 33.509 billion yuan, with a year-on-year growth of 7.3%, ranking second in the region [1] - The primary industry grew by 4.5%, the secondary industry by 7.7%, and the tertiary industry by 7.3%, indicating a balanced economic recovery [1] Project Development - Chongzuo held a major project commencement and completion ceremony in March, featuring 71 projects with a total investment of 16.4 billion yuan, including 44 new projects worth 14.4 billion yuan and 27 completed projects worth 2 billion yuan [2] Service and Support for Enterprises - The Chongzuo Work Team has been actively involved in supporting project construction, focusing on land use and other issues to facilitate the progress of key projects like the Longma Control Group's high-end equipment manufacturing base [3] - The team has also helped various enterprises, including Southern Manganese Group and China-ASEAN Nanning Airport Fusui Economic Zone, to resolve construction-related challenges, thereby improving the business environment [3] Addressing Business Challenges - The Chongzuo Work Team has addressed issues faced by local enterprises, such as the case of Guangxi Huatiangbao, which faced production challenges due to regulatory changes. The team facilitated the approval for cross-province production licenses [4] - By the end of April, the team had collected 110 feedback issues from enterprises, resolving 97 of them, achieving an 88.18% resolution rate [4] Technological Empowerment - Chongzuo is focusing on integrating technology into industry, with 46 smart manufacturing demonstration factories established in the first quarter and 26 enterprises recognized in national and regional smart manufacturing collections [6] - The Work Team has been instrumental in promoting technological innovation, including the establishment of key laboratories and partnerships to enhance the sugar industry through data-driven services [6]

Core Viewpoint - The safety concerns surrounding traditional Chinese medicine (TCM) injection solutions, particularly the case of a patient who died after receiving a Schisandra injection, have reignited discussions about the risks associated with these products and the need for improved regulatory oversight [1][3][11]. Industry Overview - The market for TCM injection solutions has seen a significant decline, with total market size dropping from 831.3 billion in 2015 to 479.8 billion in 2023, a nearly 50% reduction [7]. - Major companies in the sector, such as ST Longjin and Dali Pharmaceutical, have faced severe financial difficulties, with ST Longjin's revenue declining by 36.19% to 0.48 billion in 2024 [8][9]. - Despite the challenges, some companies remain optimistic about the potential for TCM injections, with predictions that products like Kanyuan Pharmaceutical's Hot Toxic Ning injection could benefit from increased insurance coverage and expanded indications [5]. Regulatory Environment - The National Medical Products Administration (NMPA) has been actively revising the instructions for TCM injections, adding warnings about severe allergic reactions and requiring monitoring after administration [11][12]. - Recent changes in the 2023 medical insurance drug directory have relaxed some payment restrictions on TCM injections, allowing for broader use in clinical settings [13][14]. - However, the existing risk management system still has shortcomings, such as delayed implementation of revised instructions and insufficient training for medical staff on proper medication use [12]. Safety Concerns - Reports indicate that adverse reactions to TCM injections, particularly allergic reactions, are common, especially among older patients [3][6]. - The complexity of TCM injection formulations and the potential for contamination during production contribute to safety risks [6][10]. - The industry faces ongoing scrutiny regarding the quality control of TCM injections, with calls for stricter regulations and better monitoring of adverse reactions [10][15]. Future Outlook - The TCM injection industry must navigate its way out of the current downturn by focusing on product upgrades, regulatory compliance, and enhancing safety monitoring systems [10][16]. - Companies are encouraged to adopt modern scientific methods to assess the safety of TCM injections and to implement stricter quality control measures [16].